{
  "name": "Hansa Biopharma",
  "slug": "hansa-biopharma",
  "description": "Statiskt källarkiv med kurshistorik, finansiella rapporter och regulatoriska dokument. För nordiska bolag används Nasdaq Nordic primärt och MFN endast för saknade rapportperioder.",
  "status": "complete",
  "updated_at": "2026-08-05T23:42:33Z",
  "nasdaq_status": "retrieved",
  "latest_market": "2026-08-05: stängning 34.42, volym 863575",
  "mfn_status": "resolved_no_reports",
  "mfn_count": 0,
  "nasdaq_reports_status": "retrieved",
  "reports": {
    "available": true,
    "url": "/company/hansa-biopharma/reports",
    "count": 17,
    "nasdaq_count": 17,
    "mfn_fallback_count": 0,
    "items": [
      {
        "report_key": "2026:q2",
        "period_label": "2026 Q2",
        "date": "2026-07-22",
        "title": "Kvartalsrapport Q2 2026",
        "original_title": "Hansa Biopharma rapporterar finansiella resultat för andra kvartalet och första halvåret 2026",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bede0d6ca3a696c58e3598e2e00f28e88&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2026,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2026",
            "title": "Kvartalsrapport Q2 2026",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a459bffc7616fe23ccdb6934b4a8e0002",
            "date": "2026-07-22",
            "period": "2026-q2",
            "form_type": "interim-report",
            "report_key": "2026:q2",
            "filename": "07210802.pdf",
            "text_chars": 76479,
            "sha256": "7c96a3f10c9c5b538cb7ee4f047d7edb9ec0e39e0c83068947e292c0981fd717",
            "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026",
            "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026",
            "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026/part-001.html",
                "chars": 76479
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2026:q1",
        "period_label": "2026 Q1",
        "date": "2026-04-08",
        "title": "Kvartalsrapport Q1 2026",
        "original_title": "Hansa Biopharma bjuder in till en telefonkonferens för att presentera delårsrapporten för Q1 2026",
        "category": "Nyheter för investerare",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b6e7ae8326227671800994d5edd916f72&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2026,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
            "title": "Kvartalsrapport Q1 2026",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ab155000ddcd14b8fb922b451c6cde179",
            "date": "2026-04-08",
            "period": "2026-q1",
            "form_type": "interim-report",
            "report_key": "2026:q1",
            "filename": "04086073.pdf",
            "text_chars": 2749,
            "sha256": "c8671a4d0e0bbf857b977456e4768af01c5bbb9e09f80e63c69414c2cb028229",
            "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
            "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
            "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
                "chars": 2749
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:annual",
        "period_label": "2025 Årsredovisning",
        "date": "2026-03-26",
        "title": "Årsredovisning 2025",
        "original_title": "Hansa Biopharma publicerar årsrapport och hållbarhetsredovisning för 2025",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bf27172f754e60a7443d9e24540f4d734&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2025,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2025",
            "title": "Årsredovisning 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a634d4bb5de3a51fc56afb8522e487534",
            "date": "2026-03-26",
            "period": "2025-annual",
            "form_type": "annual-report",
            "report_key": "2025:annual",
            "filename": "03250515.pdf",
            "text_chars": 445539,
            "sha256": "49d9d9919d0f1c9d567aee93c741fe03ebaaa671400b2892eb7a627a0bae2392",
            "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2025",
            "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2025",
            "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
                "chars": 178249
              },
              {
                "number": 2,
                "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
                "chars": 179453
              },
              {
                "number": 3,
                "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2025/part-003.html",
                "chars": 87833
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q4",
        "period_label": "2025 Q4",
        "date": "2026-02-11",
        "title": "Kvartalsrapport Q4 2025",
        "original_title": "Hansa Biopharma rapporterar finansiella resultat för fjärde kvartalet och helåret 2025",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b24e4656c195e7fa770fa95c24b679f75&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2025,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
            "title": "Kvartalsrapport Q4 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a55f1a964f145fc4af177885d12b6d83b",
            "date": "2026-02-11",
            "period": "2025-q4",
            "form_type": "year-end-report",
            "report_key": "2025:q4",
            "filename": "02109163.pdf",
            "text_chars": 72029,
            "sha256": "d1223c9b80e05d8e24cc6206176c82ee7c77a707cce1d8869d5739d07625970b",
            "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
            "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
            "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
                "chars": 72029
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q3",
        "period_label": "2025 Q3",
        "date": "2025-10-08",
        "title": "Kvartalsrapport Q3 2025",
        "original_title": "Hansa Biopharma bjuder in till en telefonkonferens för att presentera delårsrapporten för Q3 2025",
        "category": "Nyheter för investerare",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bcc4d4002a3afac4613c92cf153fcffe6&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
            "title": "Kvartalsrapport Q3 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a3590db052477e7010a784d8beedc6948",
            "date": "2025-10-08",
            "period": "2025-q3",
            "form_type": "interim-report",
            "report_key": "2025:q3",
            "filename": "10080337.pdf",
            "text_chars": 2668,
            "sha256": "81d8dd5069731af167e9477ed92479d1f82820bad7be0d1cc700ce44afcd146d",
            "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
            "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
            "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
                "chars": 2668
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q2",
        "period_label": "2025 Q2",
        "date": "2025-07-17",
        "title": "Kvartalsrapport Q2 2025",
        "original_title": "Hansa Biopharma redovisar resultat för andra kvartalet och delårsperioden januari-juni 2025",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=be59a800fb78e95341ebbb7d2d873cccc&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
            "title": "Kvartalsrapport Q2 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a2bd7541ee4c7707a91027cb2363ce721",
            "date": "2025-07-17",
            "period": "2025-q2",
            "form_type": "interim-report",
            "report_key": "2025:q2",
            "filename": "07160514.pdf",
            "text_chars": 74346,
            "sha256": "95329c9a7d31ef1580cad5cdec7d71cd76582fbd8615f73a353ea1ad9fe0fde6",
            "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
            "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
            "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
                "chars": 74346
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q1",
        "period_label": "2025 Q1",
        "date": "2025-04-03",
        "title": "Kvartalsrapport Q1 2025",
        "original_title": "Hansa Biopharma bjuder in till en telefonkonferens för att presentera delårsrapporten för Q1 2025",
        "category": "Nyheter för investerare",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bd966d7a0e436df1dde6f6d4892e81388&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
            "title": "Kvartalsrapport Q1 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a613ec82fbb278a21614a73ef93f20139",
            "date": "2025-04-03",
            "period": "2025-q1",
            "form_type": "interim-report",
            "report_key": "2025:q1",
            "filename": "04021269.pdf",
            "text_chars": 2581,
            "sha256": "9757e217aebb392fd75b36a374dc4017532db1289f8b5faac734b3a2c7b686a0",
            "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
            "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
            "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
                "chars": 2581
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:annual",
        "period_label": "2024 Årsredovisning",
        "date": "2025-03-21",
        "title": "Årsredovisning 2024",
        "original_title": "Hansa Biopharma publicerar årsredovisning och hållbarhetsredovisning för 2024",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b3f66e0760f0e5922e3d1f4e76da660ff&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2024,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2024",
            "title": "Årsredovisning 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/aa901e5d2cd9ac8b3aaa9618272fc2b8b",
            "date": "2025-03-21",
            "period": "2024-annual",
            "form_type": "annual-report",
            "report_key": "2024:annual",
            "filename": "03193018.pdf",
            "text_chars": 360363,
            "sha256": "7c540e35d6f3f4a0e40aa1e081539f9730535717e44ef61bda852af2bc5cbc9e",
            "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2024",
            "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2024",
            "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
                "chars": 177176
              },
              {
                "number": 2,
                "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
                "chars": 179660
              },
              {
                "number": 3,
                "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2024/part-003.html",
                "chars": 3523
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q4",
        "period_label": "2024 Q4",
        "date": "2025-02-06",
        "title": "Kvartalsrapport Q4 2024",
        "original_title": "Hansa Biopharmas bokslutskommuniké för januari-december 2024",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=baf73910900f71907e73a2e06e810b725&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2024,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
            "title": "Kvartalsrapport Q4 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ae2fb4bf053952c35f5cf2df99b8852a3",
            "date": "2025-02-06",
            "period": "2024-q4",
            "form_type": "year-end-report",
            "report_key": "2024:q4",
            "filename": "02052870.pdf",
            "text_chars": 71941,
            "sha256": "151f7539d9c6f657803854c8f80d46dd7214f9365db2e625dd84242a5350ee94",
            "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
            "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
            "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
                "chars": 71941
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q3",
        "period_label": "2024 Q3",
        "date": "2024-10-17",
        "title": "Kvartalsrapport Q3 2024",
        "original_title": "Hansa Biopharma rapporterar finansiella resultat för tredje kvartalet 2024 och delårsrapport för januari-september 2024",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bb5914c933dc4541abbf383b820629d8b&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
            "title": "Kvartalsrapport Q3 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a15b7936b44769b5c49ea28b8204c68c9",
            "date": "2024-10-17",
            "period": "2024-q3",
            "form_type": "interim-report",
            "report_key": "2024:q3",
            "filename": "10163165.pdf",
            "text_chars": 68578,
            "sha256": "53111b306a1871a47c7508f7de23599732427a104cc3e3b24b94a19c575da595",
            "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
            "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
            "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
                "chars": 68578
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q2",
        "period_label": "2024 Q2",
        "date": "2024-07-18",
        "title": "Kvartalsrapport Q2 2024",
        "original_title": "Hansa Biopharma rapporterar finansiella resultat för andra kvartalet 2024 och ger en verksamhetsuppdatering",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bef02c2bdd58381750da47d55f83e0a9c&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
            "title": "Kvartalsrapport Q2 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a91de3c49fc04dfc22b6a52fd9d24b0bc",
            "date": "2024-07-18",
            "period": "2024-q2",
            "form_type": "interim-report",
            "report_key": "2024:q2",
            "filename": "07176835.pdf",
            "text_chars": 70776,
            "sha256": "0611d6c9b6d265cd14379e5db790a6d2d0c06a59f0a3049c870534620b1f89a0",
            "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
            "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
            "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
                "chars": 70776
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q1",
        "period_label": "2024 Q1",
        "date": "2024-04-18",
        "title": "Kvartalsrapport Q1 2024",
        "original_title": "Hansa Biopharmas delårsrapport för januari-mars 2024",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b8a78401bd6b6f50fc99a2eea679a25be&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
            "title": "Kvartalsrapport Q1 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a244337ed6b472b581999f12183b6b20d",
            "date": "2024-04-18",
            "period": "2024-q1",
            "form_type": "interim-report",
            "report_key": "2024:q1",
            "filename": "04173308.pdf",
            "text_chars": 65947,
            "sha256": "0e9ae5296cff8282e0304d048ef7bb227ddadb4471c70535a7c9245c4e27b6d0",
            "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
            "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
            "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
                "chars": 65947
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:annual",
        "period_label": "2023 Årsredovisning",
        "date": "2024-03-21",
        "title": "Årsredovisning 2023",
        "original_title": "Hansa Biopharma publicerar årsredovisning och hållbarhetsrapport för 2023",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bd0aeb8c037245bb23b27782525f84674&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2023,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2023",
            "title": "Årsredovisning 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ac2ec62f7431c2add29251f632a572de0",
            "date": "2024-03-21",
            "period": "2023-annual",
            "form_type": "annual-report",
            "report_key": "2023:annual",
            "filename": "03198022.pdf",
            "text_chars": 353279,
            "sha256": "fb8b5f620dbe4273367fc8d969b17cd231b9aafa532176edf7ac960661aa5224",
            "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2023",
            "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2023",
            "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
                "chars": 175721
              },
              {
                "number": 2,
                "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
                "chars": 177556
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q4",
        "period_label": "2023 Q4",
        "date": "2024-04-02",
        "title": "Kvartalsrapport Q4 2023",
        "original_title": "Hansa Biopharma förväntar sig stark försäljningsutveckling under första kvartalet 2024",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bb817408be4d6efd33bd1a29052930c3d&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2023,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
            "title": "Kvartalsrapport Q4 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a2e5ffea0a02f73d653940969caf5f244",
            "date": "2024-04-02",
            "period": "2023-q4",
            "form_type": "year-end-report",
            "report_key": "2023:q4",
            "filename": "04014780.pdf",
            "text_chars": 4591,
            "sha256": "58dcb731cbfae3151f20aa822b0f2491697a1ff6c3e1457b02e30c125eeef6dc",
            "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
            "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
            "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
                "chars": 4591
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q3",
        "period_label": "2023 Q3",
        "date": "2023-10-26",
        "title": "Kvartalsrapport Q3 2023",
        "original_title": "Hansa Biopharmas delårsrapport januari-september 2023",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b2040e3695cb897029553b8c36c2dbbe1&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
            "title": "Kvartalsrapport Q3 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ae94c624f4ac4255a0a806a1066b6beb7",
            "date": "2023-10-26",
            "period": "2023-q3",
            "form_type": "interim-report",
            "report_key": "2023:q3",
            "filename": "10251421.pdf",
            "text_chars": 63461,
            "sha256": "5514d6c77dab35b5fc1d89254e52c8d4288ab1a10a00751190267751d9cb030a",
            "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
            "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
            "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
                "chars": 63461
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q2",
        "period_label": "2023 Q2",
        "date": "2023-07-20",
        "title": "Kvartalsrapport Q2 2023",
        "original_title": "Hansa Biopharmas halvårsrapport januari-juni 2023",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b00495dcd2f0ed6e15197ea39e54c3193&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
            "title": "Kvartalsrapport Q2 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/aa98541d31c2230c51e17bbf59b28fc40",
            "date": "2023-07-20",
            "period": "2023-q2",
            "form_type": "interim-report",
            "report_key": "2023:q2",
            "filename": "07195864.pdf",
            "text_chars": 62020,
            "sha256": "13def23a6a8ea0e34bade469c95719c3eaffdd413e934a5fd2e1a68b31488247",
            "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
            "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
            "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
                "chars": 62020
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q1",
        "period_label": "2023 Q1",
        "date": "2023-04-20",
        "title": "Kvartalsrapport Q1 2023",
        "original_title": "Hansa Biopharmas delårsrapport för januari-mars 2023",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b6130baf7050bd3f346ace8e7d36342b0&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
            "title": "Kvartalsrapport Q1 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a5e83ef50796120f143d6d264e5861db7",
            "date": "2023-04-20",
            "period": "2023-q1",
            "form_type": "interim-report",
            "report_key": "2023:q1",
            "filename": "04192209.pdf",
            "text_chars": 55710,
            "sha256": "e6869fb0bb1decdc5f18bf1677e7aa3161bacca0ecabb155b1775fb08aad5f45",
            "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
            "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
            "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
                "chars": 55710
              }
            ]
          }
        ],
        "alternatives": []
      }
    ]
  },
  "report_count": 17,
  "nasdaq_report_count": 17,
  "mfn_fallback_count": 0,
  "sec_status": "skipped",
  "sec_count": 0,
  "fi_status": "retrieved",
  "fi_summary": {
    "company": "Hansa Biopharma",
    "identity": {
      "issuer": "Hansa Biopharma AB",
      "lei": "549300LLEO25ZJJ3NT91",
      "source": "FI aggregerade blankningspositioner",
      "row_count": 13,
      "score": 118.0,
      "status": "resolved",
      "requested_company": "Hansa Biopharma",
      "query": "Hansa Biopharma AB",
      "candidate_count": 346
    },
    "period": {
      "from": "2024-08-04",
      "to": "2026-08-04",
      "years": 2
    },
    "generated_at": "2026-08-04T11:41:04Z",
    "insider": {
      "transactions": 12,
      "all_export_rows": 12,
      "acquisitions": 6,
      "disposals": 6,
      "other": 0,
      "acquisition_value_sek": 22115723.56,
      "disposal_value_sek": 23620180.46,
      "characters": {
        "Avyttring": 6,
        "Förvärv": 6
      }
    },
    "short_selling": {
      "aggregate_percent": 4.0,
      "current_public_positions": 3,
      "historical_changes": 94,
      "current_position_sum_over_0_5": 2.18
    },
    "sources": {
      "insider_register": "https://www.fi.se/sv/vara-register/insynsregistret/",
      "short_register": "https://www.fi.se/sv/vara-register/blankningsregistret/"
    }
  },
  "warnings": [
    "MFN fallback: resolved_no_reports"
  ],
  "source_identity": {
    "nasdaq_reports": {
      "slug": "hnsa",
      "instrument_id": "TX318650",
      "resolved_url": "https://www.nasdaq.com/european-market-activity/shares/hnsa?id=TX318650"
    },
    "mfn": {
      "status": "resolved",
      "company_name": "Hansa Biopharma",
      "expected_name": "Hansa Biopharma",
      "match_score": 100.0,
      "slug": "hansa-biopharma",
      "url": "https://mfn.se/all/a/hansa-biopharma",
      "metadata": {
        "country": "Sverige",
        "list": "Mid Cap Stockholm",
        "sector": "Hälsovård",
        "industry": "Bioteknik",
        "website": "https://mb.cision.com/Main/1219/4376601/4200215.pdf"
      },
      "ticker_candidates": [],
      "attempts": []
    },
    "sec": null,
    "nasdaq": {
      "instrument_id": "TX318650",
      "asset_class": "SHARES",
      "isin": "SE0002148817",
      "symbol": "HNSA",
      "company": "Hansa Biopharma",
      "market": null,
      "last_sale_price": "SEK 34.42",
      "time_as_of": "2026-08-05"
    },
    "finansinspektionen": {
      "issuer": "Hansa Biopharma AB",
      "lei": "549300LLEO25ZJJ3NT91",
      "source": "FI aggregerade blankningspositioner",
      "row_count": 13,
      "score": 118.0,
      "status": "resolved",
      "requested_company": "Hansa Biopharma",
      "query": "Hansa Biopharma AB",
      "candidate_count": 346
    }
  },
  "documents": [
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2026",
      "title": "Kvartalsrapport Q2 2026",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a459bffc7616fe23ccdb6934b4a8e0002",
      "date": "2026-07-22",
      "period": "2026-q2",
      "form_type": "interim-report",
      "report_key": "2026:q2",
      "filename": "07210802.pdf",
      "text_chars": 76479,
      "sha256": "7c96a3f10c9c5b538cb7ee4f047d7edb9ec0e39e0c83068947e292c0981fd717",
      "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026",
      "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026",
      "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2026/part-001.html",
          "chars": 76479
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
      "title": "Kvartalsrapport Q1 2026",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ab155000ddcd14b8fb922b451c6cde179",
      "date": "2026-04-08",
      "period": "2026-q1",
      "form_type": "interim-report",
      "report_key": "2026:q1",
      "filename": "04086073.pdf",
      "text_chars": 2749,
      "sha256": "c8671a4d0e0bbf857b977456e4768af01c5bbb9e09f80e63c69414c2cb028229",
      "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
      "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
      "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
          "chars": 2749
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2025",
      "title": "Årsredovisning 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a634d4bb5de3a51fc56afb8522e487534",
      "date": "2026-03-26",
      "period": "2025-annual",
      "form_type": "annual-report",
      "report_key": "2025:annual",
      "filename": "03250515.pdf",
      "text_chars": 445539,
      "sha256": "49d9d9919d0f1c9d567aee93c741fe03ebaaa671400b2892eb7a627a0bae2392",
      "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2025",
      "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2025",
      "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
          "chars": 178249
        },
        {
          "number": 2,
          "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
          "chars": 179453
        },
        {
          "number": 3,
          "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2025/part-003.html",
          "chars": 87833
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
      "title": "Kvartalsrapport Q4 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a55f1a964f145fc4af177885d12b6d83b",
      "date": "2026-02-11",
      "period": "2025-q4",
      "form_type": "year-end-report",
      "report_key": "2025:q4",
      "filename": "02109163.pdf",
      "text_chars": 72029,
      "sha256": "d1223c9b80e05d8e24cc6206176c82ee7c77a707cce1d8869d5739d07625970b",
      "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
      "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
      "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
          "chars": 72029
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
      "title": "Kvartalsrapport Q3 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a3590db052477e7010a784d8beedc6948",
      "date": "2025-10-08",
      "period": "2025-q3",
      "form_type": "interim-report",
      "report_key": "2025:q3",
      "filename": "10080337.pdf",
      "text_chars": 2668,
      "sha256": "81d8dd5069731af167e9477ed92479d1f82820bad7be0d1cc700ce44afcd146d",
      "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
      "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
      "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
          "chars": 2668
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
      "title": "Kvartalsrapport Q2 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a2bd7541ee4c7707a91027cb2363ce721",
      "date": "2025-07-17",
      "period": "2025-q2",
      "form_type": "interim-report",
      "report_key": "2025:q2",
      "filename": "07160514.pdf",
      "text_chars": 74346,
      "sha256": "95329c9a7d31ef1580cad5cdec7d71cd76582fbd8615f73a353ea1ad9fe0fde6",
      "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
      "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
      "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
          "chars": 74346
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
      "title": "Kvartalsrapport Q1 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a613ec82fbb278a21614a73ef93f20139",
      "date": "2025-04-03",
      "period": "2025-q1",
      "form_type": "interim-report",
      "report_key": "2025:q1",
      "filename": "04021269.pdf",
      "text_chars": 2581,
      "sha256": "9757e217aebb392fd75b36a374dc4017532db1289f8b5faac734b3a2c7b686a0",
      "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
      "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
      "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
          "chars": 2581
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2024",
      "title": "Årsredovisning 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/aa901e5d2cd9ac8b3aaa9618272fc2b8b",
      "date": "2025-03-21",
      "period": "2024-annual",
      "form_type": "annual-report",
      "report_key": "2024:annual",
      "filename": "03193018.pdf",
      "text_chars": 360363,
      "sha256": "7c540e35d6f3f4a0e40aa1e081539f9730535717e44ef61bda852af2bc5cbc9e",
      "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2024",
      "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2024",
      "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
          "chars": 177176
        },
        {
          "number": 2,
          "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
          "chars": 179660
        },
        {
          "number": 3,
          "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2024/part-003.html",
          "chars": 3523
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
      "title": "Kvartalsrapport Q4 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ae2fb4bf053952c35f5cf2df99b8852a3",
      "date": "2025-02-06",
      "period": "2024-q4",
      "form_type": "year-end-report",
      "report_key": "2024:q4",
      "filename": "02052870.pdf",
      "text_chars": 71941,
      "sha256": "151f7539d9c6f657803854c8f80d46dd7214f9365db2e625dd84242a5350ee94",
      "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
      "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
      "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
          "chars": 71941
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
      "title": "Kvartalsrapport Q3 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a15b7936b44769b5c49ea28b8204c68c9",
      "date": "2024-10-17",
      "period": "2024-q3",
      "form_type": "interim-report",
      "report_key": "2024:q3",
      "filename": "10163165.pdf",
      "text_chars": 68578,
      "sha256": "53111b306a1871a47c7508f7de23599732427a104cc3e3b24b94a19c575da595",
      "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
      "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
      "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
          "chars": 68578
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
      "title": "Kvartalsrapport Q2 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a91de3c49fc04dfc22b6a52fd9d24b0bc",
      "date": "2024-07-18",
      "period": "2024-q2",
      "form_type": "interim-report",
      "report_key": "2024:q2",
      "filename": "07176835.pdf",
      "text_chars": 70776,
      "sha256": "0611d6c9b6d265cd14379e5db790a6d2d0c06a59f0a3049c870534620b1f89a0",
      "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
      "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
      "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
          "chars": 70776
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
      "title": "Kvartalsrapport Q1 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a244337ed6b472b581999f12183b6b20d",
      "date": "2024-04-18",
      "period": "2024-q1",
      "form_type": "interim-report",
      "report_key": "2024:q1",
      "filename": "04173308.pdf",
      "text_chars": 65947,
      "sha256": "0e9ae5296cff8282e0304d048ef7bb227ddadb4471c70535a7c9245c4e27b6d0",
      "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
      "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
      "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
          "chars": 65947
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
      "title": "Kvartalsrapport Q4 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a2e5ffea0a02f73d653940969caf5f244",
      "date": "2024-04-02",
      "period": "2023-q4",
      "form_type": "year-end-report",
      "report_key": "2023:q4",
      "filename": "04014780.pdf",
      "text_chars": 4591,
      "sha256": "58dcb731cbfae3151f20aa822b0f2491697a1ff6c3e1457b02e30c125eeef6dc",
      "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
      "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
      "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
          "chars": 4591
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2023",
      "title": "Årsredovisning 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ac2ec62f7431c2add29251f632a572de0",
      "date": "2024-03-21",
      "period": "2023-annual",
      "form_type": "annual-report",
      "report_key": "2023:annual",
      "filename": "03198022.pdf",
      "text_chars": 353279,
      "sha256": "fb8b5f620dbe4273367fc8d969b17cd231b9aafa532176edf7ac960661aa5224",
      "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2023",
      "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2023",
      "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
          "chars": 175721
        },
        {
          "number": 2,
          "url": "/company/hansa-biopharma/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
          "chars": 177556
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
      "title": "Kvartalsrapport Q3 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ae94c624f4ac4255a0a806a1066b6beb7",
      "date": "2023-10-26",
      "period": "2023-q3",
      "form_type": "interim-report",
      "report_key": "2023:q3",
      "filename": "10251421.pdf",
      "text_chars": 63461,
      "sha256": "5514d6c77dab35b5fc1d89254e52c8d4288ab1a10a00751190267751d9cb030a",
      "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
      "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
      "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
          "chars": 63461
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
      "title": "Kvartalsrapport Q2 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/aa98541d31c2230c51e17bbf59b28fc40",
      "date": "2023-07-20",
      "period": "2023-q2",
      "form_type": "interim-report",
      "report_key": "2023:q2",
      "filename": "07195864.pdf",
      "text_chars": 62020,
      "sha256": "13def23a6a8ea0e34bade469c95719c3eaffdd413e934a5fd2e1a68b31488247",
      "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
      "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
      "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
          "chars": 62020
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
      "title": "Kvartalsrapport Q1 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a5e83ef50796120f143d6d264e5861db7",
      "date": "2023-04-20",
      "period": "2023-q1",
      "form_type": "interim-report",
      "report_key": "2023:q1",
      "filename": "04192209.pdf",
      "text_chars": 55710,
      "sha256": "e6869fb0bb1decdc5f18bf1677e7aa3161bacca0ecabb155b1775fb08aad5f45",
      "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
      "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
      "txt_url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/hansa-biopharma/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
          "chars": 55710
        }
      ]
    },
    {
      "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata",
      "title": "MFN bolagssida och bolagsmetadata",
      "source": "MFN",
      "source_class": "mfn",
      "source_url": "https://mfn.se/all/a/hansa-biopharma",
      "date": null,
      "period": null,
      "form_type": "company-page",
      "report_key": null,
      "filename": "company.txt",
      "text_chars": 14694,
      "sha256": "efcb5106d4da6aeeace43bef026a35bf8633f3814ca5d1589cde55c3b5551106",
      "url": "/company/hansa-biopharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
      "absolute_url": "https://spela.port0.org/company/hansa-biopharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
      "txt_url": "/company/hansa-biopharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/hansa-biopharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/hansa-biopharma/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html",
          "chars": 14694
        }
      ]
    }
  ],
  "market_files": [
    {
      "label": "Nasdaq kurshistorik CSV",
      "url": "/company/hansa-biopharma/market/history.csv",
      "absolute_url": "https://spela.port0.org/company/hansa-biopharma/market/history.csv"
    },
    {
      "label": "Nasdaq kurshistorik JSON",
      "url": "/company/hansa-biopharma/market/history.json",
      "absolute_url": "https://spela.port0.org/company/hansa-biopharma/market/history.json"
    },
    {
      "label": "Nasdaq manifest JSON",
      "url": "/company/hansa-biopharma/market/manifest.json",
      "absolute_url": "https://spela.port0.org/company/hansa-biopharma/market/manifest.json"
    },
    {
      "label": "Nasdaq instrumentidentitet JSON",
      "url": "/company/hansa-biopharma/market/instrument.json",
      "absolute_url": "https://spela.port0.org/company/hansa-biopharma/market/instrument.json"
    },
    {
      "label": "SEC sammanfattning JSON",
      "url": "/company/hansa-biopharma/market/sec-summary.json",
      "absolute_url": "https://spela.port0.org/company/hansa-biopharma/market/sec-summary.json"
    },
    {
      "label": "MFN manifest JSON",
      "url": "/company/hansa-biopharma/market/mfn-manifest.json",
      "absolute_url": "https://spela.port0.org/company/hansa-biopharma/market/mfn-manifest.json"
    },
    {
      "label": "Nasdaq rapportmanifest JSON",
      "url": "/company/hansa-biopharma/market/nasdaq-reports-manifest.json",
      "absolute_url": "https://spela.port0.org/company/hansa-biopharma/market/nasdaq-reports-manifest.json"
    }
  ],
  "sec_facts": {
    "status": "missing",
    "metrics": []
  },
  "morningstar": {
    "configured": true,
    "status": "retrieved",
    "captured_at": "2026-08-01T01:57:05Z",
    "view_count": 4,
    "url": "/company/hansa-biopharma/morningstar",
    "path": "D:\\Web\\aktieanalys\\public\\company\\.hansa-biopharma.tmp\\morningstar",
    "files": [
      "index.html",
      "summary.txt",
      "screenshot.png"
    ]
  },
  "finansinspektionen": {
    "available": true,
    "status": "retrieved",
    "url": "/company/hansa-biopharma/finansinspektionen",
    "transaction_count": 12,
    "aggregate_short_percent": 4.0,
    "files": [
      {
        "filename": "summary.json",
        "label": "Sammanfattning JSON",
        "url": "summary.json"
      },
      {
        "filename": "insider-transactions.csv",
        "label": "Insynstransaktioner CSV",
        "url": "insider-transactions.csv"
      },
      {
        "filename": "insider-transactions.json",
        "label": "Insynstransaktioner JSON",
        "url": "insider-transactions.json"
      },
      {
        "filename": "short-current.json",
        "label": "Aktuella blankningspositioner JSON",
        "url": "short-current.json"
      },
      {
        "filename": "short-history.json",
        "label": "Historiska blankningspositioner JSON",
        "url": "short-history.json"
      },
      {
        "filename": "short-aggregate.json",
        "label": "Aggregerad blankning JSON",
        "url": "short-aggregate.json"
      },
      {
        "filename": "manifest.json",
        "label": "Hämtningsmanifest JSON",
        "url": "manifest.json"
      }
    ]
  },
  "llms_url": "/company/hansa-biopharma/llms.txt",
  "json_url": "/company/hansa-biopharma/company.json",
  "document_index_url": "/company/hansa-biopharma/documents.json",
  "absolute_url": "https://spela.port0.org/company/hansa-biopharma"
}